Haleon plc stock (GB00BMX86B70): Consumer health giant eyes growth in US OTC market

Haleon plc, the world's largest standalone consumer health company, is expanding its presence in the US over-the-counter market as it seeks to drive growth amid rising demand for self-care products.

Haleon plc, the world's largest standalone consumer health company, is expanding its presence in the US over-the-counter market as it seeks to drive growth amid rising demand for self-care products. The company, which was spun off from GSK in 2022, has a portfolio of well-known brands such as Sensodyne, Panadol, and Advil, and is leveraging its strong brand recognition to capture a larger share of the US OTC market.

As of 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Haleon plc
• Sector/industry: Consumer health
• Headquarters/country: United Kingdom
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: Oral care, pain relief, respiratory, vitamins and supplements
• Home exchange/listing venue: London Stock Exchange (ticker: HLN)
• Trading currency: GBP

Haleon plc: core business model

Haleon plc operates as a global consumer health company, focusing on over-the-counter (OTC) products that address everyday health needs. The company's business model is built on a portfolio of trusted brands that are widely recognized by consumers for their quality and effectiveness. Haleon's strategy is to invest in innovation, marketing, and distribution to maintain and grow its market share in key categories such as oral care, pain relief, and respiratory health.

The company's products are sold through a variety of channels, including pharmacies, supermarkets, and online retailers. Haleon's strong relationships with these retailers enable it to reach a broad customer base and ensure that its products are readily available to consumers. The company also benefits from its global footprint, which allows it to leverage economies of scale and share best practices across different markets.

Main revenue and product drivers for Haleon plc

Haleon's main revenue drivers are its leading brands in the oral care, pain relief, and respiratory categories. Sensodyne, the company's flagship oral care brand, is the world's number one toothpaste for sensitive teeth and has a strong presence in the US market. Panadol, a leading pain relief brand, is widely used for the treatment of headaches, fever, and other common ailments. Advil, another key pain relief brand, is known for its fast-acting formula and is a popular choice among consumers.

In addition to these core brands, Haleon has a growing portfolio of vitamins and supplements that cater to the increasing demand for products that support overall health and wellness. The company's focus on innovation has led to the development of new products that address emerging consumer needs, such as products that support immune health and digestive wellness. These new products are expected to contribute to Haleon's revenue growth in the coming years.

Conclusion

Haleon plc is well-positioned to benefit from the growing demand for consumer health products, particularly in the US OTC market. The company's strong brand portfolio, global footprint, and focus on innovation provide a solid foundation for long-term growth. However, investors should be aware of the competitive nature of the consumer health industry and the potential for regulatory changes that could impact the company's operations. Overall, Haleon plc represents an interesting opportunity for investors seeking exposure to the consumer health sector.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.

Media_Description: Haleon plc headquarters building exterior

Tags: Haleon plc, consumer health, US OTC market

ISIN: GB00BMX86B70

Summary:

Haleon plc, the world's largest standalone consumer health company, is expanding its presence in the US over-the-counter market as it seeks to drive growth amid rising demand for self-care products.

The company's main revenue drivers are its leading brands in the oral care, pain relief, and respiratory categories, including Sensodyne, Panadol, and Advil.

Haleon plc is well-positioned to benefit from the growing demand for consumer health products, particularly in the US OTC market, but investors should be aware of the competitive nature of the industry and potential regulatory changes.